Clinical Trials Logo

Filter by:
NCT ID: NCT03776071 Completed - Glioblastoma Clinical Trials

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Start date: December 16, 2020
Phase: Phase 3
Study type: Interventional

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 3 study. Approximately 300 subjects with newly diagnosed glioblastoma who meet all eligibility criteria will be enrolled.

NCT ID: NCT03775850 Completed - Bladder Cancer Clinical Trials

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

Start date: December 19, 2018
Phase: Phase 1
Study type: Interventional

This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors

NCT ID: NCT03775694 Completed - Healthy Clinical Trials

Diffusion MRI-1 Imaging Database

dMRI-1
Start date: June 6, 2019
Phase:
Study type: Observational

The purpose of the dMRI-1 data collection study is to establish a database of clinical images and limited medical history information from patients that have previously received a dMRI scan. All data collected will be de-identified. No safety or effectiveness assessments will be completed.

NCT ID: NCT03775200 Completed - Clinical trials for Treatment Resistant Depression

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

P-TRD
Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression

NCT ID: NCT03773991 Completed - Clinical trials for End Stage Renal Disease

Dyspnea Assessment in Hemodialysis Patients

Start date: March 29, 2019
Phase:
Study type: Observational

Shortness of breath is very common among patients on dialysis for kidney failure; however, its causes are often not understood. This study will explore the lungs and the heart of these patients to determine the causes of shortness of breath. The amount of salt in the body tissues, which tends to accumulate in dialysis patients and can also cause shortness of breath, will also be measured. Machines that exploit magnetic resonance, ultrasound and x-rays to take images of the body interior will be employed; in addition, breathing tests, questionnaires and blood tests will also be used. 20 patients on dialysis will be recruited and have two visits: one at the beginning of the study and one year later to observe any changes in the lungs, heart and salt accumulation over time.

NCT ID: NCT03773380 Completed - Lung Cancer Clinical Trials

Breathe Anew for Lung Cancer Survivorship

BA
Start date: January 2, 2019
Phase: Phase 1
Study type: Interventional

Survivorship programs have become an integral component of modern cancer care programs. In Canada, there has been tremendous success for survivorship programs for breast, prostate, and colorectal cancer, however lung cancer survivorship programs have not been widely developed. The complexity of the disease, high mortality, short survival times, high cost of surveillance, and patient habits have traditionally been barriers against the success of lung cancer survivorship programs. The investigator proposes a feasibility study to pilot a novel intervention titled Breathe Anew, which will aim to identify and overcome the barriers to the design and implementation of a lung cancer survivorship program. The investigator has assembled a multi-disciplinary team of experts and lung cancer survivors who will develop the Breathe Anew survivorship intervention. The intervention will be vetted using an integrated knowledge translation approach, which will involve members of the target population, primarily patients who previously underwent lung resection, to modify the intervention and ensure acceptability. After Breathe Anew has been designed, it will be tested in a pilot study of 50 patients to ensure its feasibility and determine its cost. The ultimate goal of this feasibility study is to lay the groundwork for a subsequent comparative trial to evaluate the impact of Breathe Anew on patient-important outcomes including health related quality and length of life and postoperative complications.

NCT ID: NCT03772665 Completed - Stargardt Disease Clinical Trials

Safety and Efficacy of Emixustat in Stargardt Disease

SeaSTAR
Start date: January 7, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if emixustat hydrochloride reduces the rate of progression of macular atrophy compared to placebo in subjects with Stargardt disease. Funding Source -- FDA OOPD

NCT ID: NCT03772587 Completed - Clinical trials for Generalized Myasthenia Gravis

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

Start date: April 10, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of M281 administered to participants with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing standard of care therapy.

NCT ID: NCT03772574 Completed - Preoxygenation Clinical Trials

Preoxygenation Using THRIVE Versus Facemask in Parturients

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

This study aims to determine the duration for pre-oxygenation using THRIVE and facemask for parturients.

NCT ID: NCT03772522 Completed - Homelessness Clinical Trials

The Identity Project

TIP
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

Understanding how to create successful pathways out of homelessness is crucial. Thirty young people (aged 18 - 26 years) who have transitioned out of homelessness within the past three years will be offered scholarships to participate in a six week intervention that focuses on building identity capital (sense of purpose and control, self-efficacy and self-esteem) and providing career direction. The intervention will be designed and carried out by dk Leadership - an established, highly successful leadership and counseling centre in Toronto with a track record of significantly improving the life trajectories of teens and adults. Importantly, study participants will be incorporated into the centre's current programming, meaning the intervention will be held at a location not associated with homelessness. Study participants will be collaboratively recruited by dk Leadership and Covenant House Toronto - Canada's largest agency for street-involved and homeless youth. This impact and process evaluation aims to address critical gaps in knowledge about transition-related supports by asking whether and how an identity capital intervention delivered outside the social service sector impacts the life-trajectories of formerly homeless young people. Particular attention will be paid to whether this intervention shows promise as an unconventional way to tackle poverty and improve social inclusion. It is hypothesize that, for the primary quantitative outcome measures of hope, community integration, social connectedness, and self-esteem: 1. Significant improvements in the mean scores of the intervention group compared to the delayed intervention comparison group immediately post-intervention will be observed. 2. Significant improvements in the mean scores of both groups (intervention and delayed intervention) immediately post-intervention will be observed. 3. These significant improvements will be sustained in both groups for at least three months post-intervention.